tbuckley/cabot-search huggingface dataset:
AB0331 Incidence and Predictors of Cardiovascular Events Over a Period of 5 Years in a Cohort of Women with Rheumatoid Arthritis: Table 1.
Authors: A.M. Castro, D. Carmona-Fernandes, H.M. Canhão, J.E. Fonseca, M.J. Santos
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> An excess in cardiovascular (CV) morbidity and mortality has been recognized in Rheumatoid Arthritis (RA) patients when compared to the general population. <h3>Objectives</h3> Our aim was to estimate the incidence of CV events and the contribution of traditional CVD risk factors and RA-related parameters to future events. <h3>Methods</h3> Incident fatal and non-fatal CV events (hospitalizations due to unstable angina, myocardial infarction, coronary artery revascularization procedures, stroke, or CV death) were assessed in a prospective cohort of RA women followed since 2007 and without CV events at cohort entry. The presence of traditional CV risk factors, disease characteristics, medication, carotid ultrasound, and biomarkers of inflammation and endothelial activation were evaluated at baseline. Univariate Cox proportional hazard models were used to identify risk factors for CV events. <h3>Results</h3> Among 106 women followed over 565 patient-years we identified 4 CV events (1 fatal stroke, 2 myocardial infarction and 1 unstable angina), which contributed to an incidence rate of 7 per 1000 person-years (95%CI 2.0-13.9). Patients who developed CV events were older, but the distribution of other traditional CV risk factors was otherwise similar in both groups. Also, corticosteroid dosage and proportion of patients with carotid atherosclerotic plaques was higher in those with CV events (Table 1). Erythrocyte sedimentation rate (ESR) (HR 1.036; 95%CI 1.005-1.067) and soluble intercellular adhesion molecule-1 (sICAM-1) serum levels (HR 1.002; 95%CI 1.000-1.003) significantly contributed to CV events. These results remained significant after adjusting for patients9 age. <h3>Conclusions</h3> We found an incidence of cardiovascular events in women with RA of 7 per 1000 patent-years. This value is similar to that found in other Portuguese cohort of RA patients1 and much higher than the incidence reported for the general Portuguese population. Markers of inflammation and endothelial activation contributed significantly to CV events, but the limited number of events prevents further analysis. <h3>References</h3> Santos MJ, et al. The incidence of cardiovascular events among rheumatoid arthritis patients in Portugal. Ann Rheum Dis 2009;68 (Suppl3):406 <h3>Disclosure of Interest</h3> None declared
PTU-144 The influence of gastric cancer screening upon stage at diagnosis and survival
Authors: SR Markar, E Khanderia, A Acharya, GB Hanna
Journal: Gut (2015)

<h3>Introduction</h3> Gastric is the fifth most common cancer and second most common cause of cancer-related death worldwide. The aim of this review is to evaluate the effect of gastric cancer screening upon stage at diagnosis and survival from disease. <h3>Method</h3> A systematic review of the literature between January 1995 and December 2014 was performed. All studies that compared screened vs. non-screened populations for the diagnosis of gastric cancer and included an outcome of stage at diagnosis were analysed. The QUADAS-2 tool was used to assess the quality of the studies. <h3>Results</h3> 11 studies comprising 4039 in the screened and 6635 in non-screened groups were included. Screening was associated with a significant increase in the detection of early gastric cancer (POR = 3.90; 95% C. I. 3.01 to 5.06; P &lt; 0.0001) and reduction in the incidence of advanced gastric cancer (POR = 0.27; 95% C. I. 0.20 to 0.35; P &lt; 0.0001). Furthermore screening significantly improved 5-year survival (POR = 0.56; 95% C. I. 0.48 to 0.66; P &lt; 0.0001). The overall diagnostic accuracy for barium radiography was good as illustrated by summary ROC analysis with an area under the curve of 0.95 ± 0.01. QUADAS-2 assessment highlighted potential biases within the reference standards. <h3>Conclusion</h3> Screening for gastric cancer is useful in detecting asymptomatic patients with early gastric cancer in high prevalence areas. This in turn, increases the number of treatable cancers and improves five-year survival. There is a need for the development and validation of alternative risk-stratification tools in low incidence areas to allow for similar benefits. <h3>Disclosure of interest</h3> None Declared.
Structural Details of Some of the Epithelial Cell Types in the Kidney of the Mouse as Revealed by the Electron Microscope
Authors: Albert J. Dalton
Journal: JNCI Journal of the National Cancer Institute (1951)

Structural Details of Some of the Epithelial Cell Types in the Kidney of the Mouse as Revealed by the Electron Microscope Get access Albert J. Dalton Albert J. Dalton National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 6, June 1951, Pages 1163–1185, https://doi.org/10.1093/jnci/11.6.1163 Published: 01 June 1951 Article history Received: 30 January 1951 Published: 01 June 1951
PTH-019 Palliative stenting for inoperable oesophageal cancer: results of a national survey of health professionals
Authors: R Driver, S Kite, G Radhakrishna, P Wright, M Hull, S Everett
Journal: Gut (2015)

<h3>Introduction</h3> In recent years, the role of oesophageal stenting for malignant dysphagia has evolved alongside other palliative treatments for oesophageal cancer. Management has become increasingly multidisciplinary and different considerations affect decisions about the timing and appropriateness of palliative stenting. We sought to assess the current UK practice of palliative stenting in oesophageal cancer. We assessed which specialties perform the procedure, which technique is used, the use of anti-reflux stents and investigated how different clinicians involved in the care of these patients would recommend managing dysphagia in different clinical scenarios. <h3>Method</h3> An online survey was sent out to the professional bodies of the members of the Upper GI MDT. Opinions of health professionals including gastroenterologists, oncologists, palliative care physicians, surgeons, radiologists and nurse specialists on the benefits and discomfort associated with the procedure were evaluated. Four clinical scenarios were used to evaluate opinions on maintaining nutrition prior to stenting, stenting in end-of-life care and the role of the MDT. <h3>Results</h3> The survey received 239 respondents, including 92 individuals (39%) who regularly insert oesophageal stents (‘stenters’). 63% of stents are inserted via endoscopy with fluoroscopic guidance, 20% with fluoroscopic guidance alone and 17% with endoscopy alone. 74% of responders never use anti-reflux devices, irrespective of the involvement of the gastro-oesophageal junction. 92% of respondents considered that stenting improved long-term dysphagia. Among the stenters, 20% considered that patients experience significant discomfort with some distress during the procedure (compared with 43% of non-stenters) and 16% during the days post-procedure (compared with 55% of non-stenters). 92% of stenters consider that the procedure improves quality of life in the 4 weeks post-procedure, compared with 78% of non-stenters. The clinical scenarios revealed that 15% of respondents would recommend stenting in end of life care in a patient who was managing a semi-solid diet, whereas 44% would consider stenting only if swallowing deteriorated subsequently. In complete dysphagia, 40% of respondents would recommend awaiting MDT discussion prior to oesophageal stent placement. <h3>Conclusion</h3> Health professionals’ perceptions of patient discomfort and improvement in quality of life are associated with the individuals’ experience of performing oesophageal stent insertion. These perceptions may influence decisions about timing and indication for oesophageal stenting. Care should be taken to acknowledge this, alongside the variation in opinion among clinicians over optimal management in different scenarios. <h3>Disclosure of interest</h3> None Declared.
A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.
Authors: Roy S. Herbst, Alfonso Gurpide, Veerle Surmont, Dong-Wan Kim, Saiama Naheed Waqar, Judith Herder, Dae Ho Lee, Enric Carcereny, Noemi Reguart, John M. Wallmark, Suresh S. Ramalingam, Corey J. Langer, Gregory M. Lubiniecki, James Knowles, Honghong Zhou, Mary Elizabeth Hanson, Paul Baas
Journal: Journal of Clinical Oncology (2014)

TPS8124 Background: Docetaxel is a standard second line treatment for patients with advanced non-small cell lung cancer (NSCLC). It yields a low response rate (~10.5%), limited 1-year survival rate (~37%), and median overall survival (OS) of ~ 7.5 months. MK-3475 is a highly selective anti-PD-1 monoclonal antibody exerting dual ligand blockade (DLB) of the PD-1 pathway, a major pathway hijacked by tumors to suppress immune control. Preclinical and clinical data suggest that this pathway plays an important role in NSCLC. Upon interaction with its ligands, PD-L1 and PD-L2, the activation of PD-1 may lead to suppression of antitumor immunity. This randomized phase II/III trial was designed to assess the clinical activity of MK-3475 monotherapy compared with standard docetaxel in patients with advanced NSCLC whose disease has progressed after platinum-containing therapy. Methods: Eligibility stipulates minimum age of 18 years; ECOG performance status of 0-1, and diagnosis of advanced PD-L1-positive NSCLC with documented progression after platinum-containing systemic therapy. Patients are stratified by ECOG performance status, geographic location of the site, and degree of PD-L1 expression and randomized in a 1:1:1 ratio to receive intravenous MK-3475 (2 mg/kg, every 3 weeks [Q3W] or 10 mg/kg, Q3W) or docetaxel (75 mg/m2, Q3W) for 2 years or until disease progression, unacceptable toxicity, intercurrent illness or investigator decision. Response to treatment will be evaluated every 9 weeks by investigators using the immune-related response criteria (irRC) and centrally by RECIST 1.1. Adverse events (AEs) will be monitored throughout the trial. Primary objectives include OS and PFS per RECIST 1.1 in patients with strong expression of PD-L1, and safety, including incidence and time to first Grade 3-5 AE. Secondary objectives include OS, PFS and ORR per RECIST 1.1 in patients with PD-L1 positive tumors. Fifty of approximately 920 pts targeted for accrual have enrolled. Clinical trial information: NCT01905657.
The Lithium Index: an innovative approach to consultation by computer
Authors: D L Ackerman, J W Jefferson, J H Greist, M G Baudhuin, J Vukovich
Journal: American Journal of Psychiatry (1984)

The Lithium Index, a computer consultation program, was developed at the Lithium Information Center to quickly provide up-to-date information about lithium and its side effects. Information is contained in brief summaries that are compiled from the literature, organized by clinical topic, and written and retrieved by means of an interactive computer program. Computer-stored texts are easily updated to incorporate new information. The authors present an example that deals with the use of lithium during pregnancy, the most frequently requested topic.
THU0234 Long-Term Efficacy of Infliximab in Patients with Ankylosing Spondylitis – Real Life Data Confirm the Potential for Dose Reduction by Stretching Infusion Intervals
Authors: X. Baraliakos, F. Heldmann, F. van den Bosch, G.-R. Burmester, H. Gaston, I. van der Horst-Bruinsma, B. Andermann, A. Krause, R. Schmidt, M. Schneider, J. Sieper, M. Witt, J. Braun
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Long-term data on anti-TNF treatment in patients with ankylosing spondylitis (AS) are still scarce. <h3>Objectives</h3> To study the long term efficacy and safety of anti-TNF agents in AS in a pan-European setting using data from daily practice. <h3>Methods</h3> Patients from the EASIC and the DIKAS trial had been included in this 8-year observational study. Clinical data were collected every 2 years. All patients were initially treated with infliximab at the usual dosage (5mg/kg). Standard assessments were regularly performed, and adverse events (AEs) and serious AEs (SAEs) were documented. The data are presented as completer analysis. <h3>Results</h3> Of initially 71 patients, 55 (77.5%) were included in this long-term extension study (46 male, 83.6%). Of these 55 patients, 7 (12.7%) switched from infliximab to another biologic for different reasons. At the end of the study, 31 patients (56.4%) received NSAIDs in addition to TNF-blockers. The mean doses of infliximab remained stable over time (4.7±0.6 mg/kg, min: 3.6, max: 6.4) but the infusion intervals increased (7.1±1.5 weeks, range 6-12 weeks). There was no correlation between the duration of infusion interval and the disease status achieved by the patients. Overall, the mean BASDAI (baseline (BL): 6.4, 2y: 2.4, 8y: 2.5), BASFI (BL: 5.9, 2y: 2.9, 8y: 3.5), BASMI (BL: 4.0, 2y: 2.7, 8y: 3.9), patient9s global (BL: 7.0, 2y: 2.9, 8y: 2.9), and CRP (mg/dl) values (BL: 2.9, 2y: 0.6, 8y: 0.4) remained low throughout the entire observation period. The majority of adverse events were mild, most of them were respiratory tract infections. Two malignancies occurred: one basal cell carcinoma and one malignant melanoma, all during the first 7 years of treatment. These two were the only SAE judged to be possibly related to the study drug. <h3>Conclusions</h3> This study confirms the favourable outcome of AS patients who complete anti-TNF therapy over many years. The persistently decreased BASDAI, BASFI and BASMI values suggest a good control of disease activity, in combination with preserved function and spinal mobility over 8 years. The observation that infusion intervals could be prolonged confirms that dose reduction of anti-TNF therapy is feasible. <h3>Disclosure of Interest</h3> None declared
Stereo Cinefluorography—The Heart in 3-D
Authors: G G ROWE
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0093 Efficacy of Radiation Synovectomy (Radiosynovectomy or Radiosynoviorthesis) with Yttrium-90 (Y-90) in Exudative Inflammation of Synovial Membrane of Knee Joints in Patients with Rheumatic Diseases:
Authors: J. Zalewska, I. Dankiewicz-Fares, R. Wojciechowski, S. Jeka
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Hypertrophic and exudative synovitis of knee is one of the earliest symptoms in rheumatic diseases. In case of pharmacotherapy failure, other methods which directly remove the inflamed synovial membrane- synovectomies are used. Radiosynovectomy (RSV) is a radiopharmaceutical admission of colloidal solution to cavity joints. <h3>Objectives</h3> In this publication, the authors decided to assess the efficacy of knee RSV with Yttrium-90 (Y-90) in several groups of patients with rheumatic diseases.We have also proposed the algorithm for patients with recurrent knee effusion. <h3>Methods</h3> The study group was 100 patients in age from 20 to 82 years with hypertrophic-exudative synovitis of knee in rheumatic diseases (47 patients with RA, 33 patients with OA, 10 patients with psoriatic arthritis and 10 patients with AS). Radiopharmaceutical colloid of Y-90, with radiation dose 185-222 MBq in a volume of 2-3 ml, was administered to joint. The knee was immobilized for 72 h. The effect of treatment was monitored by the use of objective methods: evaluation of acute phase indicators- ESR and CRP, ultrasound- evaluation of synovial hypertrophy, joint effusion quantity and synovial vascularisation in power color Doppler and subjective methods, which include the assessment of patient questionnaires (HAQ, SF-36, FACIT, EQ- 5D, WOMAC), VAS-Visual Analogue Scale pain intensity by patient and the VAS-Visual Analogue Scale disease activity by patient and physician. The visits were performed at 1, 3 and 6 months after RSV. <h3>Results</h3> In all groups of patients, we have noticed a statistically significant change concerning the reduction of synovial hypertrophy, the quantity of synovial fluid and synovial membrane activity in power color Doppler option decrease assessed in ultrasound examination. We have observed the best treatment efficacy in patients with RA.We have also noticed significant improvement in the assessment of health status in the whole group of patients, according the questionnaires: HAQ, SF-36, EQ-5D and FACIT, VAS pain assessed by patient and VAS disease activity assessed by patient and physician. <h3>Conclusions</h3> RSV is an effective and safe method of treatment hypertrophic-exudative synovitis of knee, which is resistant to use of pharmacological drugs and intraarticular glucocorticosteroids injections. In therapeutic algorithm RSV should be located between conservative treatment and operative procedures. RSV does not require hospitalization and prolonged rehabilitation. <h3>Disclosure of Interest</h3> None declared
Star Material
Authors: E Shin
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Method for Preparing Wound Washings and Bloody Fluids for Cytologic Evaluation
Authors: Sara H. DeWitt, Pasco R. Del Vecchio, Jacqueline I. Borelli, Albert W. Hilberg
Journal: JNCI Journal of the National Cancer Institute (1957)

A Method for Preparing Wound Washings and Bloody Fluids for Cytologic Evaluation Get access Sara H. DeWitt, Sara H. DeWitt National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Pasco R. Del Vecchio, Pasco R. Del Vecchio National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Jacqueline I. Borelli, Jacqueline I. Borelli National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Albert W. Hilberg Albert W. Hilberg National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 19, Issue 1, July 1957, Pages 115–121, https://doi.org/10.1093/jnci/19.1.115 Published: 01 July 1957 Article history Received: 05 February 1957 Published: 01 July 1957
Relationship between dosage and response to lithium prophylaxis in recurrent depression
Authors: R F Prien, E M Caffey
Journal: American Journal of Psychiatry (1976)

The authors analyzed the results of a multihospital collaborative study on the effectiveness of lithium prophylaxis in recurrent depression in terms of dosage and found that serum lithium levels between 0.5 and 0.7 mEq/liter and doses below 1000 mg/day were relatively ineffective in preventing recurrences. Serum lithium levels between 0.8 and 1.0 mEq/liter and doses above 1000 mg/day were associated with a relatively low failure rate. The authors discuss the relevance of these findings to current prescription guidelines for lithium carbonate.
LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
Authors: K. Park, E.-H. Tan, L. Zhang, V. Hirsh, K. O'Byrne, M. Boyer, J.C.-H. Yang, T. Mok, M. Kim, D. Massey, V. Zazulina, L. Paz-Ares
Journal: Annals of Oncology (2015)
AB0326 The Influence of Long Permanent Remission and Low Disease Activity on the Functional and Radiological Outcomes of Rheumatoid Arthritis
Authors: Y.A. Ermakova, D.E. Karateev, E.L. Luchikhina, N.V. Demidova, A.V. Smirnov, E.L. Nasonov
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Disease activity is the main of the factors, which influence on the evolution of rheumatoid arthritis (RA). The timely supression of the disease activity and the remission/low activity support prevents the development of functional and structural disorders in patients with early RA. <h3>Objectives</h3> To investigate the influence of long remission/low activity support on the functional and radiological outcomes. <h3>Methods</h3> We used the data of long-term Russian project "RADICAL" (Early Arthritis: Diagnostic, Outcomes, Criterions, Aggressive Treatment). 200 patients with early RA (diagnosed for less than two year) according to American College of Rheumatology criteria included in the study from 2003 to 2007 (67,5% RF (+); 57% ACCP (+), 86,5% women, age of 49 [40-58]). Patients followed for 5 years. They were treated by DMARDs including the biologic therapy (24%) according the "tight-control" principle. The radiological investigation of hands and feet, DAS28, HAQ and functional class evaluated every 12 months. <h3>Results</h3> From 1 to 5 years of follow-up the number of patients with permanent remission was 28 (group 1), the number of patients with remission/low activity – 26 (group 2), with permanent activity (group 3) – 26, with recurrent RA (group 4) – 120. After 5 years of follow-up HAQ &gt;0,5 has been verified in 7% (group 1), 23% (group 2), 100% (group 3), 62% (group 4), p&lt;0,001. SHS (M±σ) was 37,93±18,98, 35,42±15,11, 69,84±38,70 and 51,45±30,06, respectively, p&lt;0,001. <h3>Conclusions</h3> Patients with long permanent remission and low disease activity will benefit with better functional ability and will have less radiological damage. <h3>Disclosure of Interest</h3> None declared